Lucica® MI urinary myoinositol kit: A new diagnostic test for diabetes mellitus and glucose intolerance

Molecular Diagnosis and Therapy

Volumn 12, Issue 3, 2008, Pages 189-191

  Yamakoshi, Masaru ^a   Kawazu, Shoji ^b  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; INOSITOL;

CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEALTH CARE COST; HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; URINE LEVEL; ANALYTICAL EQUIPMENT; ARTICLE; COMPARATIVE STUDY; EVALUATION; GLUCOSE TOLERANCE TEST; URINE;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INOSITOL; REAGENT KITS, DIAGNOSTIC;

EID: 44449141997     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256283     Document Type: Short Survey

References (12)

1. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4
2. Nóvoa FJ, Boronat M, Saavedra P, et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diabetes Care 2005 Oct; 28 (10): 2388-93
3. Oizumi T, Daimon M, Jimbu Y, et al. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample: the Funagata study. Metabolism 2008 Mar; 57 (3): 333-8
4. Blake DR, Meigs JB, Muller DC, et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 2004 Aug; 53 (8): 2095-100
5. Muntner P, He J, Chen J, et al. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004 Oct; 14 (9): 686-95
6. Lim SC, Tai ES, Tan BY, et al. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care 2000 Mar; 23 (3): 278-82
7. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (6): 393-403
8. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000; 23: 1563-80
9. Yamakoshi M, Takahashi M, Kouzuma T, et al. Determination of urinary myo-inositol concentration by an improved enzymatic cycling method using myo-inositol dehydrogenase from Flavobacterium sp. Clin Chim Acta 2003; 328 (1-2): 163-71
10. Yamagata F, Kawazu S, Tominaga M, et al. Determination of urinary myo-inositol at 75g oral glucose tolerance test: comparisons of normal, borderline and diabetic types, and setting of cut-off value by ROC analysis. Jpn J Med Pharm Sci 2004; 52 (6): 975-80
11. Kawazu S, Tominaga M, Yamagata F, et al. Determination of urinary myo-inositol: comparison of glucose intolerance group with normal type. Jpn J Med Pharm Sci 2004; 52 (6): 981-7
12. Sarashina G, Yamakoshi M, Noritake M, et al. A study of urinary myo-inositol as a sensitive marker of glucose intolerance. Clin Chim Acta 2004; 344 (1-2): 181-8